Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology by Alain Moreau, PhD, Montreal Collaboration

From the desk of Dr. Alain Moreau, PhD
Director of the Collaborative Research Center 
at the CHU Sainte-Justine/Université de Montréal

#TripleGivingTuesday Research Update

Montréal ME/CFS Research Center Paper
Published in Scientific Reports

On behalf of Open Medicine Foundation (OMF), I am pleased to share that an article authored by my research team at the OMF Funded ME/CFS Collaborative Research Center (CRC) at Université de Montréal has been published online by Scientific Reports!

You might remember in my last update from the Research Center at Montréal, I shared a brief update about this study, entitled “Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology,” and our groundbreaking discovery and validation of different microRNAs associated with ME/CFS.

MicroRNAs can represent potential indicators for diseases such as ME/CFS, and changes in microRNA expression could indicate cellular dysfunction and degeneration. Using a test to induce mild-but-reproducible Post Exertional Malaise (PEM), our team has so far uncovered and validated 11 different microRNAs associated with ME/CFS that are capable of differentiating ME/CFS patients from healthy patients — wit 90 percent accuracy! 

This post-exertional stress challenge provoking PEM in ME/CFS patients has helped us gain unprecedented insight into the pathophysiology of ME/CFS. Based on the 11 different microRNA signatures discovered in ME/CFS, machine learning algorithms have also led to the classification of ME/CFS patients into four clusters associated with symptom severity.

These exciting results could lead to the development of a new, non-invasive diagnostic test for ME/CFS, a prognostic tool used to predict future cases, and identification of effective treatment options.

Read the full paper

Thank you to all who have supported our work. It is through your donations, small and large, and your belief in our mission to end ME/CFS, that we have been given the opportunity to advance research with confidence and urgency.

Join us in this outstanding effort to uncover answers as we boldly move closer to the discovery of a diagnostic test, treatments, and a cure for ME/CFS.

Join us in this outstanding effort to uncover answers as we boldly move closer to the discovery of a diagnostic test, treatments, and a cure for ME/CFS.

All donations to OMF will be TRIPLED from now until December 1, giving you the exciting opportunity to TRIPLE your support of this innovative research.

It’s with your support that we’re leading critical research and delivering hope for millions. 


Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager